Silverberg, Jonathan I.; Gooderham, Melinda; Katoh, Norito; Aoki, Valeria 
; Pink, Andrew E.; Binamer, Yousef; Glick, Brad; Staubach, Petra; Calimlim, Brian; Li, Chao
Source: Dermatology and Therapy. Unidade: FM
Subjects: DERMATITE DE CONTATO, RESULTADO DE TRATAMENTO, QUALIDADE DE VIDA, ENSAIO CLÍNICO, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVERBERG, Jonathan I. et al. Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase 3 studies (Measure Up 1 and 2). Dermatology and Therapy, v. 15, n. 9, p. 2583-2594, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/89159. Acesso em: 06 maio 2026.APA
Silverberg, J. I., Gooderham, M., Katoh, N., Aoki, V., Pink, A. E., Binamer, Y., et al. (2025). Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase 3 studies (Measure Up 1 and 2). Dermatology and Therapy, 15( 9), 2583-2594. doi:10.1007/s13555-025-01485-0NLM
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Glick B, Staubach P, Calimlim B, Li C. Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase 3 studies (Measure Up 1 and 2) [Internet]. Dermatology and Therapy. 2025 ; 15( 9): 2583-2594.[citado 2026 maio 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/89159Vancouver
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Glick B, Staubach P, Calimlim B, Li C. Achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate-to-severe atopic dermatitis: integrated analysis of phase 3 studies (Measure Up 1 and 2) [Internet]. Dermatology and Therapy. 2025 ; 15( 9): 2583-2594.[citado 2026 maio 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/89159
